Prebiotic Fiber as a Modifier of Satiety Hormones and Body Weight in Overweight and Obese Adults

University of Calgary

Status: Completed

Conditions: Obesity

Treatments: Dietary Supplement: Placebo; Dietary Supplement: Oligofructose

Study type: Interventional

Funder types: Other

Identifiers

NCT00522353

UC 20085

Details and patient eligibility

About

The purpose of this study is to determine if oligofructose supplementation promotes weight loss in overweight and obese adults.

Full description

Obesity is a primary health concern for many western countries as it is linked to several chronic diseases as well as, large health care costs. Although obesity is a multifactorial disease, it is known that levels of satiety hormones including glucagon like peptide-1 (GLP-1) and peptide YY (PYY) are reduced in obesity. The ability of prebiotic fiber to promote weight loss through the production of satiety hormones has been tested previously using rodents. Here it was found that prebiotic supplementation resulted in a decreased energy intake, higher GLP-1 levels in the plasma and increased proglucagon mRNA levels in the gut. This study will address the important question of whether prebiotic fiber supplementation is effective in reducing body weight in overweight or obese human subjects.

Enrollment: 48 patients

Sex: All

Ages: 20 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• overweight or class I obese individuals with BMI between 25 kg/m2 and 34.9 kg/m2
• stable body weight in previous 3 months

Exclusion criteria

• Type 1 and Type 2 diabetes
• clinically significant cardiovascular abnormalities
• liver or pancreas disease
• major gastrointestinal surgeries
• are pregnant or lactating
• exhibit alcohol or drug dependence
• on drugs influencing appetite
• are following a diet or exercise regime designed for weight loss
• have a body mass greater than 350lb
• chronic use of antacids or bulk laxatives

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

48 participants in 2 patient groups, including a placebo group

1

Active Comparator group

Description:

Oligofructose

Treatment:

Dietary Supplement: Oligofructose

2

Placebo Comparator group

Description:

Placebo

Treatment:

Dietary Supplement: Placebo